Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1777-1784

  Ringdén, Olle ^a   Brazauskas, Ruta ^b   Wang, Zhiwei ^b   Ahmed, Ibrahim ^c   Atsuta, Yoshiko ^d   Buchbinder, David ^e   Burns, Linda J ^f   Cahn, Jean Yves ^g   Duncan, Christine ^h   Hale, Gregory A ⁱ   Halter, Joerg ^j   Hayashi, Robert J ^k   Hsu, Jack W ^l   Jacobsohn, David A ^m   Kamble, Rammurti T ⁿ   Kamani, Naynesh R ^o   Kasow, Kimberly A ^p   Khera, Nandita ^q   Lazarus, Hillard M ^r   Loren, Alison W ^s   Marks, David I ^t   Myers, Kasiani C ^u   Ramanathan, Muthalagu ^v   Saber, Wael ^v   Savani, Bipin N ^w   Schouten, Harry C ^x   Socie, Gérard ^y   Sorror, Mohamed L ^z   Steinberg, Amir ^aa   Popat, Uday ^ab   Wingard, John R ^l   Mattsson, Jonas ^a   Majhail, Navneet S ^ac   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k ST LOUIS CHILDREN S HOSPITAL   (United States)

^l UNIVERSITY OF FLORIDA   (United States)

^m CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁿ CENTER FOR CELL AND GENE THERAPY   (United States)

^o AABB   (United States)

^p UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^q MAYO CLINIC   (United States)

^r UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^s UNIVERSITY OF PENNSYLVANIA   (United States)

^t BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^u CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^v UMASS MEMORIAL MEDICAL CENTER   (United States)

^w VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^x MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^y SAINT LOUIS HOSPITAL   (France)

^z UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^aa Sinai Medical Center   (United States)

^ab UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ac LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Hematopoietic cell transplantation; Nonmyeloablative conditioning; Reduced intensity conditioning; Second cancers; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONTROLLED STUDY; CUTANEOUS MELANOMA; DONOR LYMPHOCYTE INFUSION; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY CANCER; LARYNX CANCER; LIP CANCER; LIVER CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OROPHARYNX CANCER; PANCREAS CANCER; PROSTATE CANCER; RECTUM CANCER; REDUCED INTENSITY CONDITIONING; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RISK FACTOR; SECOND CANCER; SMALL INTESTINE CANCER; SOFT TISSUE CANCER; SOLID TUMOR; STANDARDIZED INCIDENCE RATIO; TESTIS CANCER; TONGUE CANCER; TONSIL CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VULVA CANCER; WHOLE BODY RADIATION; ADOLESCENT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84908022945     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.009     Document Type: Article

References (35)

1. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. NEngl J Med 1997, 336:897-904.
2. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. NEngl J Med 1993, 329:1152-1157.
3. Witherspoon R.P., Fisher L.D., Schoch G., et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. NEngl J Med 1989, 321:784-789.
4. Baker K.S., DeFor T.E., Burns L.J., et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. JClin Oncol 2003, 21:1352-1358.
5. Majhail N.S., Brazauskas R., Rizzo J.D., et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011, 117:316-322.
6. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
7. Majhail N.S. Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol 2011, 154:301-310.
8. Friedman D.L., Rovo A., Leisenring W., et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008, 111:939-944.
9. Majhail N.S., Rizzo J.D., Lee S.J., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:348-371.
10. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
11. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. JClin Oncol 2006, 24:444-453.
12. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. JClin Oncol 1998, 16:2817-2824.
13. McSweeney P.A., Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999, 5:192-203.
14. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. JClin Oncol 2005, 23:1993-2003.
15. Bornhauser M., Kienast J., Trenschel R., et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012, 13:1035-1044.
16. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003, 102:2021-2030.
17. Ringden O., Erkers T., Aschan J., et al. Aprospective randomized toxicitystudy to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. JIntern Med 2013, 274:153-162.
18. Ringden O., Labopin M., Ehninger G., et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. JClin Oncol 2009, 27:4570-4577.
19. Garwicz S., Anderson H., Olsen J.H., et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 2000, 88:672-678.
20. Travis L.B., Holowaty E.J., Bergfeldt K., et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. NEngl J Med 1999, 340:351-357.
21. van Leeuwen F.E., Chorus A.M., van den Belt-Dusebout A.W., et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. JClin Oncol 1994, 12:1063-1073.
22. Le Deley M.C., Leblanc T., Shamsaldin A., et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. JClin Oncol 2003, 21:1074-1081.
23. Shimoni A., Shem-Tov N., Chetrit A., et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia 2013, 27:829-835.
24. Clark T.G., Altman D.G., De Stavola B.L. Quantification of the completeness of follow-up. Lancet 2002, 359:1309-1310.
25. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
26. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2012. Available at: http://www.cibmtr.org.
27. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
28. Horner MJ, Ries LAG, Krapcho M, etal. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2006/.
29. Cox D.R. Regression models and life tables. JR Stat Soc 1972, 34:187-202.
30. Curado MP, Edwards B, Shin HR, etal. Cancer incidence in five continents, Vol. IX. International Agency for Research on Cancer Scientific Publications No. 160. Lyon, France,2007.
31. Breslow NE, Day NE. The design and analysis of cohort studies. In: Statistical methods in cancer research, Vol. II. International Agency for Research on Cancer Scientific Publications No. 82. Lyon, France,1987.
32. Majhail N.S. Old and new cancers after hematopoietic-cell transplantation. Hematology Am Soc Hematol Educ Progr 2008, 142-149.
33. Socie G., Curtis R.E., Deeg H.J., et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. JClin Oncol 2000, 18:348-357.
34. Bhatia S., Ramsay N.K., Steinbuch M., et al. Malignant neoplasms following bone marrow transplantation. Blood 1996, 87:3633-3639.
35. Yokota A., Ozawa S., Masanori T., et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant 2012, 47:95-100.